kas iskelet sistemi hastalıkları farmakolojisi

Question 1

Agents effecting on bone mineral
density

Answer 1

*Vitamin D
* Calcitonine
* Biphosphonates
* Calcimimetics
* Denosumab
* Parathormon analogs

Question 2

parathormon sentezini baskılar,
ancak hiperkalsemik etkileri bulunmaz, sekonder
hiperparatiroidi tedavisinde kullanılır

Answer 2

vitamin d analoglari

Question 3

vit D preparatları

Answer 3

kolekalsiferol
kalsitriol
vit D deriveleri
vit D analogları

Question 4

CALCITONIN

Answer 4

treatment of acute hypercalcemia IV, SC
*– Paget disease
– Prevention of BMD loss related to acute immobility
– Osteoporosis—-**nasal formulation

Question 5

Osteoclast inhibition and apoptosis of osteoclastsr

Answer 5

Bisphosphonates

Question 6

Bisphosphonates
* Classification:

Answer 6

first generation–non nitrogenated—inactivate ATP molecules in osteoclasts
second generation–alkyl amino group–apoptosis of osteoclasts due
to the lack of synthesis of isopyrenoid precursors

third generations–heterocyclic hydrogen group-apoptosis of osteoclasts due
to the lack of synthesis of isopyrenoid precursors

Question 7

Bisphosphonates dverse effect

Answer 7

– GERH, eusophagitis
-renal toxicity
-flu like symptoms
-femoral fractures

Question 8

inhbiity RANK ligand activity drugs

Answer 8

Denosumab

Question 9

adverse effect of denosumab

Answer 9

similar to biphosphonates effect but not renal toxicity

Question 10

Biologic DMARDs targets

Answer 10

role for RA
development:
– Anti-TNF-alfa
– Anti-IL-6
– Anti-IL-1
– JAK-STAT inhibitors (JAKi)
– T-cell modulators
– Anti-B cell

Question 11

what kind of Syntetic DMARDs – csDMARDS

Answer 11

gold, penicilamine, metotraxate, sulphasalazine,Hydroxychloroquine

Question 12

• Most important adverse effect QT prolongation

Answer 12

Hydroxychloroquine

Question 13

Generally combined with metotrexate and
hydroxycloroquine → better tolerability with
combination

Answer 13

sulphasazaline